"Top Takeaways From ASH: ELOQUENT-2 Trial Results of Elotuzumab Demonstrate Immune Effects"
Ajai Chari, MD, director of clinical research in the Multiple Myeloma Program at The Mount Sinai Hospital, commented on the results of ELOQUENT-2 in the broader context of the recently approved agents for multiple myeloma. Learn more.
Press Release
New Insights Revealed On Tissue-Dependent Roles of JAK Signaling in Inflammation
Dec 21, 2023 View All Press Releases